C5 and paroxysmal nocturnal hemoglobinuria: Fortunately, data are becoming available suggesting that eculizumab, the first complement component 5 (C5) inhibitor approved for patients with PNH [8], can improve pregnancy outcomes for women with PNH and their infants [6,7].